FDA Approves Medtronic’s BrainSense Personalized Brain Stimulation Device For Parkinson’s Disease

The U.S. Food and Drug Administration (FDA) approved Medtronic’s BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI) as treatment to control Parkinson’s disease motor symptoms. The system self-adjusts DBS therapy to the user’s brain activity in real-time, which minimizes the need for users to manually adjust the device stimulation to control motor symptom fluctuations, dyskinesias, and other side effects.

DBS uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by neurological disorders. Medtronic has enhanced its Percept™ DBS neurostimulators . . .